Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels.
The aim of this study was to clarify the relationship between human leukocyte antigen DR allele distribution and the degree of liver cell injury of hepatitis C virus (HCV) carriers in Japan. The subjects, 68 HCV carriers, were divided into two groups according to the laboratory data and liver histology. Those in the asymptomatic carrier group (n = 19) had normal ALT levels persistently for 8-153 months (mean 25.7 months) and were diagnosed histologically as normal liver, nonspecific reactive hepatitis or chronic persistent hepatitis. Those in the chronic active hepatitis group (n = 49) had elevated ALT levels and were diagnosed histologically with chronic active hepatitis. The human leukocyte antigen DR alleles of all subjects were defined using the polymerase chain reaction restriction fragment length polymorphism method. The expression of human leukocyte antigen class I antigen and intercellular adhesion molecule 1 on the hepatocyte membrane were also examined in 14 patients from each group using an indirect immunohistochemical method. The frequency of DR13 (42.1%) in the asymptomatic carrier group was significantly higher (Pc < 0.003) than that of the chronic active hepatitis group (4.1%). There were no significant differences for the other DR alleles. The frequencies of expression of human leukocyte antigen class I antigen and intercellular adhesion molecule 1 on the hepatocyte membrane of the asymptomatic carrier group were significantly less than those of the chronic hepatitis group (64% vs. 100% P < 0.05, 29% vs. 71% P < 0.05, respectively), although there was no significant difference in the serum HCV-RNA titer between the two groups (10(6.4 +/- 1.1) vs. 10(6.5 +/- 0.7) copies/mL). These results demonstrate that the cellular immune response of the asymptomatic carrier group is less activated than the response of the chronic active hepatitis group and that HLA DR13 may be closely associated with this low activity of hepatitis among HCV carriers.
Kuzushita
N
N
First Department of Medicine, Osaka University School of Medicine, Japan.
Hayashi
N
N
Katayama
K
K
Hiramatsu
N
N
Yasumaru
M
M
Murata
H
H
Shimizu
Y
Y
Yamazaki
T
T
Fushimi
H
H
Kotoh
K
K
Kasahara
A
A
Fusamoto
H
H
Kamada
T
T
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000378:metabolism; D001483:Base Sequence; D002353:Carrier State / Q000276:immunology* / Q000821:virology; D017931:DNA Primers; D005260:Female; D005838:Genotype; D006684:HLA-DR Antigens / Q000235:genetics*; D059810:HLA-DR Serological Subtypes; D016174:Hepacivirus / Q000235:genetics*; D006521:Hepatitis, Chronic / Q000276:immunology* / Q000821:virology; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D006650:Histocompatibility Testing; D006801:Humans; D007150:Immunohistochemistry; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data
D017931:DNA Primers; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; C097337:HLA-DR13 antigen; D015395:Histocompatibility Antigens Class I; D018799:Intercellular Adhesion Molecule-1; D000410:Alanine Transaminase